Aandeel SLNO SOLENO THERAPEUTICS, INC.
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen Soleno Therapeutics, Inc.

Aandelen

SLNO

US8342033094

Beurs gesloten - Nasdaq
Andere beurzen
 22:00:00 25-06-2024 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
38,94 USD -2,84% Intraday-grafiek van Soleno Therapeutics, Inc. -7,06% -3,25%
11/06 Transcript : Soleno Therapeutics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 04:00 PM
06/06 Transcript : Soleno Therapeutics, Inc. - Shareholder/Analyst Call

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Soleno Therapeutics : June 2024 Corporate Presentation
Soleno Therapeutics to Join Russell 3000 Index
Soleno Therapeutics Set to Join Russell 3000® Index
Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024
Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024
Soleno Therapeutics to Participate in Upcoming Investor Conferences
Soleno Therapeutics Stands with the Prader-Willi Syndrome Community
Soleno Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Soleno Therapeutics Prices $138 Million Stock Offering
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock
Soleno Therapeutics Announces Proposed Public Offering of Common Stock
Soleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi Syndrome
Soleno Therapeutics, Inc. Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to Natural History of Prader-Willi Syndrome
Soleno Therapeutics' Shares Jump After FDA Grants Breakthrough Designation for Prader-Willi Syndrome Treatment
Soleno Therapeutics Gets Breakthrough Therapy Designation for Diazoxide Choline
Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)
Soleno Therapeutics, Inc. Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome
Soleno Therapeutics, Inc. Announces Gwen Melincoff, Intends Not Intend to Stand for Re-Election as Director
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers SLNO
  4. Nieuws Soleno Therapeutics, Inc.
  5. Andere talen